The development of semaglutide: from lab discovery to licensed weight-loss medicine

What natural process did researchers start from when developing semaglutide?

The starting point was not a lab bench experiment but a meal. When you eat, your gut releases a hormone called glucagon-like peptide-1 (GLP-1). It signals fullness to the brain, prompts the pancreas to release insulin in proportion to rising blood sugar, and slows the rate at which food leaves the stomach. The problem is that GLP-1 in its natural form lasts about two minutes in the bloodstream before enzymes break it down.

Scientists at Novo Nordisk, building on foundational GLP-1 biology mapped out in the 1980s and 1990s, set out to create a molecule that could mimic those effects for long enough to be therapeutically useful. Their earlier compound, liraglutide, achieved a 24-hour half-life by attaching a fatty-acid chain that binds loosely to albumin in the blood. The full discovery timeline for liraglutide and semaglutide shows how one molecule directly informed the other. Semaglutide took that logic further, substituting one amino acid (alanine at position 8, replaced with alpha-methylalanine) to block the main enzymatic cleavage site, then attaching a longer, more complex fatty-acid chain via a short linker. The result is a half-life close to seven days, long enough for a once-weekly injection.

That structural precision is not a footnote. It is the reason semaglutide behaves so differently from natural GLP-1, and why the researchers who developed it received significant scientific recognition for the work.

How did the clinical trial programme turn that molecule into a licensed medicine?

Regulatory approval requires evidence in humans, and Novo Nordisk ran a large trial programme called STEP (Semaglutide Treatment Effect in People with obesity) to generate it. STEP 1 (1,961 adults with obesity or overweight plus at least one weight-related condition, no type 2 diabetes, 68 weeks) is the anchor study. Participants on 2.4 mg semaglutide lost around 15% of body weight on average, compared with about 2.4% on placebo. The trial was published in the New England Journal of Medicine and formed the core of the regulatory submission.

The MHRA authorised Wegovy for weight management in adults with a BMI of 30 or above (or 27 or above alongside at least one weight-related condition) alongside a reduced-calorie diet and increased physical activity. NICE subsequently recommended it (TA875) for use within specialist weight management services, subject to BMI thresholds and a two-year maximum treatment period under NHS conditions. The Wegovy treatment overview covers what that means in practice today.

Development did not stop at 2.4 mg. A higher 7.2 mg dose was approved by the MHRA in January 2026, with a dedicated single-dose pen confirmed in April 2026. And in June 2026 the MHRA approved the first oral GLP-1 for weight management in the UK (Wegovy tablets) making it the first such approval in Europe. Each step followed the same pattern: molecular refinement, clinical evidence, regulatory scrutiny.

Why did semaglutide become a weight-loss medicine when it started as a diabetes treatment?

Semaglutide was first developed and licensed for type 2 diabetes under the brand name Ozempic (0.5 mg, 1 mg, 2 mg doses). It was during those diabetes trials that a consistent, striking side observation appeared: participants were losing substantial amounts of weight. That signal prompted dedicated obesity trials at higher doses (eventually 2.4 mg weekly) designed specifically around weight as the primary outcome rather than blood glucose.

It is worth being precise here, because the distinction matters clinically. Ozempic and Wegovy both contain semaglutide, but they carry different UK licences, different approved doses, and different indications. More on what semaglutide is and how the two products relate is covered separately. The NHS is clear that Ozempic is licensed for type 2 diabetes, not weight loss; prescribing it off-label for weight management is not supported by NHS guidance on semaglutide. Wegovy is the product developed and licensed specifically for weight management, and it is the version a prescriber would consider for that purpose.

Understanding this history also explains the titration schedule: doses start low (0.25 mg) and increase gradually over months. That escalation pattern was not arbitrary, it was the approach the STEP trials used to manage gastrointestinal side effects, and it carried straight through into the licensed dosing schedule.

What does semaglutide's development history mean for someone considering treatment today?

Decades of research and a well-documented regulatory path mean that semaglutide's mechanism, effects and side-effect profile are among the most studied of any weight-management medicine currently licensed in the UK. That does not mean it is suitable for everyone, the prescriber who reviews your consultation makes that call, based on your health history, current medicines and circumstances.

If you are weighing up whether treatment makes sense for you, the weight-loss treatment overview sets out the landscape. For those who have already decided they want to explore semaglutide specifically, guidance on accessing Wegovy through a regulated pharmacy covers what a legitimate, legal route looks like in the UK. And if cost is part of your thinking, the semaglutide cost context page explains what private treatment typically involves.

At nume, a real prescriber reads every consultation (not a decision algorithm) and your medicine, if approved, arrives via DPD the next working day in plain, unbranded packaging. No one answering the door would know what is inside. That level of clinical oversight reflects exactly what a medicine with this development pedigree warrants. If you want to find out whether treatment is right for you, start your free consultation and hear from our clinical team directly.